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A B S T R A C T
Background: Most breast cancers express the estrogen receptor alpha (ERa+), harbor wt TP53, depend on
estrogen/ERK signalling for proliferation, and respond to anti-estrogens. However, concomittant
activation of the epidermal growth factor receptor (EGFR)/MEK pathway promotes resistance by
decreasing estrogen dependence. Previously, we showed that retroviral transduction of mutant p53
R175H into wt TP53 ERa+ MCF-7 cells induces epidermal growth factor (EGF)-independent proliferation,
activation of the EGF receptor (p-EGFR) and some characteristics of epithelial-mesenchymal transition
(EMT).
Purpose: To investigate whether p53 inactivation augments ERa+ cell proliferation in response to
restrictive estradiol, chemical MEK inhibition or metabolic inhibitors.
Results: Introduction of mutant p53 R175H lowered expression of p53-dependent PUMA and
p21WAF1, decreased E-cadherin and cytokeratin 18 associated with EMT, but increased the %
of proliferating ERa+/Ki67 cells, diminishing estrogen dependence. These cells also exhibited
higher proliferation in the presence of MEK-inhibitor UO126, reciprocally correlating with
preferential susceptibility to the pyruvate analog 3-bromopyruvate (3-BrPA) without a comparable
response to 2-deoxyglucose. p53 siRNA silencing by electroporation in wt TP53 MCF-7 cells also
decreased estrogen dependence and response to MEK inhibition, while also conferring susceptibility
to 3-BrPA.
Conclusions: (a) ERa+ breast cancer cells dysfunctional for TP53 which proliferate irrespective of low
estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming
increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to
endocrine therapy in ERa+ breast cancer with p53 dysfunction.
 2014 The Authors. Published by Elsevier Inc.   
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Breast cancer is an important cause of death in women with
prevalence increasing with age [1]. Hormone receptor status is one
of the main differentiating characteristics of human breast cancers
and modiﬁes therapeutic response. Estrogen receptor alpha (ERa)Abbreviations: mutant p53 R175H, mutant p53 Arg 175His; wt, wild type; ERa,
estrogen receptor alpha; 3-BrPA, 3-bromopyruvate; E2, estradiol; EMT, epithelial–
mesenchymal transition..
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Open access under CC BY-NC-ND licsignaling plays an important role in many tissues, including the
mammary gland, where it is required for normal gland develop-
ment and maintenance. About 65% of human breast cancers are
ERa positive [1–3]. When dysregulated, ERa induces abnormal
proliferation helping in the initiation and progression of breast
cancer [2,3]. Frequent co-expression of ERa+ and the proliferation-
associated marker Ki-67 occurs with ERa+ breast cancer progres-
sion, but this is rare in the normal premenopausal human breast
[2,3]. Genetic changes affecting the tumor suppressor p53 gene are
reported in about 25% of human breast cancers [4,5]. Mutant p53
R175H is a hotspot mutation in the zinc-binding region, which
loses p53-dependent tumor-suppressor activities, but is believed
to acquire new oncogenic promoting functions [6,7]. Despite the
correlation of p53 cancer mutations and poor prognosis of human
breast cancer patients [6–8], the roles of p53 cancer mutants in
promoting breast cancer and their relationship to estrogens are ense.
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protein directly and represses its function [8]. However, despite
harboring wild-type p53, ERa+ breast cancer cells are resistant
to chemotherapy-induced apoptosis in the presence of estrogen
[9–14]. Epithelial–mesenchymal transdifferentiation (EMT) in-
volving loss of E-cadherin with disruption of epithelial cytoarch-
itecture from a cobblestone-like appearance to an elongated
mesenchymal phenotype, is another characteristic of breast
cancer progression involving mutant p53R175H [15]. Previously,
we showed that loss of E-cadherin characteristic of EMT, EGF-
independent proliferation and activation of EGFR were augment-
ed in mutant p53 transduced MCF-7 cells compared to their
genetically-matched wt p53 counterparts [15]. A single copy of
point-mutated p53 sufﬁces to make mammary cells sensitive to
the EMT response driven by TGF b [16] and matrix-metallopro-
tease activation [17–19]. EMT as an important morphologic and
developmental change involves an extensive cytoskeletal rear-
rangement [20,21] including de novo expression of mesenchymal
vimentin [22]. Cytoskeletal reorganization in EMT and breast
cancer progression also can include down-regulated expression of
cytokeratin 18 [20,23]. Restoration of cytokeratin 18 in human
breast cancer cells induces a dramatic regression of malignancy in
vitro and in vivo [20,23,24] possibly because keratin 18
expression is also involved in ERa+ mediated signaling [25]. A
study using estrogen-dependent breast cancer cell lines with
different p53 status revealed that p53 mutated cells were more
resistant to cytotoxic effects of 4-hydroxy-tamoxifen (OHT)
compared to p53 wild-type cells [4]. Estrogenic activation is
likely to induce MEK/ERK signaling and downstream phospho-
p90RSK expression, reﬂecting the importance of the Ras/Raf/ERK/
p90RSK pathway activation signal in the response of ER-positive
breast cancer [26–30]. Blockade of the MAPK/ERK signaling
cascade with the MEK inhibitor U0126 inhibits ERa activity via
enhanced recruitment of the co-repressor SMRT, leading to
reduced expression of ERa target genes and to slower growth rate
of MCF-7 cells treated with both TAM and U0126 [29,30]. Since
p53 mutations [6,7], aberrant ERa/MEK/ERK signaling [8–13,26–
32] and resistance to genotoxic stress [33] cooperate to promote
breast cancer, in this paper we investigated in genetically-
matched ERa+ MCF-7 cells, whether mutant p53 R175H increases
EMT, secretion of matrix metalloproteases [34] and loss of
cytokeratin 18 [20,23–25] together with augmenting prolifera-
tion independently of estradiol and MEK signalling. Since ERa+
breast cancer cells develop resistance to endocrine therapies by a
mechanism involving estrogen receptor (ERa+)-regulated and
growth factor receptor-regulated survival pathways [35] and Bcl-
2 over-expression in human breast cancer cells [36], we also
investigated whether speciﬁc Bcl-2/Bcl-xL antisense sequences
[37] inﬂuence ERa-linked proliferation in a p53-dependent
manner. Finally, since glucose consumption may be stimulated
by hyper-proliferation under restrictive amounts of exogenous
estrogen and EGF [15,36,38,39], we have now investigated
whether ERa+ breast cancer cells differing in p53 status respond
unequally to metabolic antagonists like the glycolytic inhibitor 2-
deoxyglucose [40] or to 3-bromopyruvate (3-BrPA), an agent that
potentially may inhibit both glycolysis and mitochondrial
function [41–43].
2. Materials and methods
2.1. Retroviral transduction and veriﬁcation of p53 status in cells
Experiments were performed with MCF-7 human breast
carcinoma cells obtained from the ATCC. These cells harbour a
functional wt p53, as evidenced by high activation of the p21WAF1
gene product [15,33,44]. To obtain p53 mutant cells, parentalMCF-7 cells were retrovirally transduced as follows: Phoenix cells
were transfected with the pWZL-Hygro plasmid harbouring a
human p53 histidine-175 mutant gene, a dominant-negative p53
mutant plasmid, in the presence of calcium chloride, as previously
described [15]; control cells were retrovirally transduced with the
empty pWZL-Hygro plasmid.
2.2. Transient p53 siRNA silencing
This was carried out using the Neon electroporation system
(Invitrogen Cat No. MPK5000, Carlsbad, CA. 92208, USA) contain-
ing 1.5  106 cells resuspended in 100 ml buffer R (Cat No.
MPK10025R) and 4 ml containing 10 nM of p53 siRNA (H) duplex
standardized to silence p53 (Cat # SC-29435). Cells were treated in
parallel with a comparable concentration of negative control
siRNA-A (Cat # SC-36868), a non-targeting duplex of the same
length as the speciﬁc p53 siRNA. Both siRNA types were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA 95060, USA). Cells
were subjected to electroporation using 2 pulses (width 30 and
1150 voltage) and subsequently seeded to 35% conﬂuence in
medium devoid of antibiotics in 96 well plates. After 12 h, cultures
were washed and subjected to the indicated treatments in
charcoal-treated estrogen-depleted medium for further assays
within 48 h.
2.3. Relative cell viability/metabolic activity
This was estimated with Alamar Blue (Catalog Number
DAL1025, Life Technologies, Carlsbad, CA 92208, USA), which
measures intracellular redox mitochondrial activity by quantitat-
ing the cell-catalyzed conversion of non-ﬂuorescent resazurin to
ﬂuorescent resoruﬁn [33]. Alamar Blue was added to a 10% ﬁnal
concentration to each one of 96 well plates after the appropriate
treatment, the dye is non-toxic, allows ﬂuorescent quantitation,
permits re-use for further investigation such as morphological,
biochemical and clonogenic analyses. As such, this assay is
valuable as an endpoint of proliferation or relative viability/
metabolic activity, rather than a kinetic measure for monitoring
cell growth. For these experiments, cells (10,000) were allowed to
adhere overnight in 96 well TC microtiter dishes. After the
corresponding treatments, Alamar Blue was added without
removing medium containing dead cells, and ﬂuorescence was
measured 4 h later in a Fluoroskan Ascent microplate reader with
an excitation of 544 nm and an emission of 590 nm.
2.4. Immune blotting
Cells were harvested in PBS containing protease and phospha-
tase inhibitors using a rubber policeman and lysates were
obtained, as described [33]. Extracts were prepared in cell lysis
buffer (50 mM Tris–HCl, pH 8, 120 mM NaCl, 50 mM NaF, 0.1 mM
sodium vanadate, 5 mM EDTA, 10 mg/mL each of leupeptin,
soybean trypsin inhibitor, and aprotinin, 1 mM phenylmethyl-
sulfonyl ﬂuoride, 0.4% Nonidet P-40). 50 mg of protein per lane run
in parallel with prestained MW markers (Life Technologies,
Gaithersburg, Md 20877, USA) was loaded into each well of an 11%
SDS–polyacrylamide gel and electrophoretically separated. Pro-
teins in the gels were transferred bi-directionally by diffusion
blotting onto replicate nitrocellulose membranes [33]. After
protein transfer, the membranes were blocked for 2 h at room
temperature with TBS (Tris-buffered saline, pH 7.5) containing 0.1%
Tween-20 and 5% nonfat skim milk, and membranes were reacted
overnight with speciﬁc antibodies in the same blocking solution.
Whenever necessary, blot pairs were erased by heating (70 8C;
30 min) with 62 mM Tris–HCl, 2% SDS, 100 mM b-mercaptoethanol.
The stripped blots were then washed extensively with 0.1%
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set of primary antibodies. In each case, detection was accomplished
by reaction with peroxidase-conjugated secondary antibody and
Super Signal chemiluminescence (Pierce Chemical, Rockford, IL
61105, USA). Antibodies used for speciﬁc immune blotting were
rabbit antibodies to p21WAF1 (SC-397), PUMA (SC-28226), mouse
monoclonal antibodies to p53 (DO-1; SC-126), cyclin A (SC-751),
Ki67 (SC-15-402), and E-cadherin (SC-8426), all obtained from Santa
Cruz Biotechnology (Santa Cruz, CA 95060, USA). Monoclonal
antibody to actin (Cat # CP01, JLA-20) was from Oncogene Research
(San Diego, CA 92121, USA). After extensive washing to remove non-
speciﬁc binding, membranes were reacted with anti mouse IgG-
peroxidase for detection of mouse antibodies, or with Protein A-
peroxidase for detection of rabbit antibodies. Loading control bands
came from the stripped blot of the target protein, or from replicate
nitrocellulose from the bi-directional blots. Densitometric quanti-
tation of differential protein expression was achieved by digitaliza-
tion of images, avoiding saturation density and choosing adequate
dynamic range with a Fluor-S Imager (Bio-Rad, Hercules, CA 94547,
USA). This was followed by quantitation of speciﬁc bands with the
Gel Pro Analyzer software (Media Cybernetics, Silver Spring, MD
20850, USA).
2.5. Crystal violet staining of surviving cells
Cells were subjected to 3-bromopyruvate, at the concentrations
indicated in each experiment. Subsequently, the unattached dead
population was removed after washing twice in isotonic phos-
phate-buffered saline. Surviving cells were evidenced following
ﬁxation in 90% ethanol and cell staining with 0.5% crystal violet
(Cat # C-3886, Sigma–Aldrich, St. Louis, MO 63103, USA) in 30%
ethanol.Fig. 1. Mutant p53 R175H induces epithelial–mesenchymal transition, extracellular MMP
with mutant p53 R175H were seeded in Lab-Tek 8 well slides and allowed to grow for 3
losses in epithelial intercellular E-cadherin and cytoskeletal keratin 18 in mutant p53
activation of the wt p53-activated p21WAF1 and PUMA, lowers the expression of E-cad
associated cyclin A. The results shown were representative of 2 different experiments. (C)
different clones of each cell type.2.6. Laser scanning cytometry (LSC)
An LSC-2 cytometer (Compucyte, Cambridge, MA 02139, USA),
which measures ﬂuorescence of individual cells contoured on the
basis of nuclear DNA counterstain with propidium iodide was used.
Every sample was scanned using identical non-saturating ﬂuores-
cence settings, to allow quantitative comparisons to be made [15].
To analyze ﬂuorescence changes only on individual cells, clustered
aggregates were gated out, to quantitate integral (total ﬂuores-
cence within the integral contour) and maximal pixels (highest
localized ﬂuorescence within the threshold contour). After the
indicated culture condition, cells attached to LabTek multiwell
plates were ﬁxed in 4% paraformaldehyde in phosphate-buffered
saline (PBS), followed by permeabilization with 0.25% Triton X-
100, washing in PBS, blocking in 5% albumin (in PBS), then reacted
with monoclonal antibodies to human cyclin A (SC-751), Ki67 (SC-
15-402), and ERa (SC-542) from Santa Cruz Biotechnology (Santa
Cruz, CA 95060, USA). All these antibodies were validated for
speciﬁc immune ﬂuorescence. Negative controls were stained with
secondary antibody without primary antibody. Multi-label detec-
tion was achieved by reaction with corresponding secondary
antibodies conjugated to either Oregon Green (Molecular Probes,
Eugene, OR, USA) for excitation with an Argon laser or Cy5 (Jackson
ImmunoResearch Laboratories Inc., West Grove, PA, USA) for Long
Red detection with an HeNe laser. Integral contouring was done by
staining DNA with propidium iodide in the red region [15], using
the corresponding blocking ﬁlters.
2.7. Immunoﬂuorescence
Subconﬂuent cultures were seeded in complete medium on 8-
well LabTek plates pre-coated with 5 mg/ml ﬁbronectin. When-2 and loss of cytokeratin 18. (A) Vector-transduced MCF-7 cells or those transduced
 days, following by ﬁxation and permeabilization as indicated in Section 2. Note the
 transfected cells. (B) Immune blotting shows that mutant p53 R175H prevents
herin and cytokeratin 18, and reciprocally increases in vimentin and proliferation-
 Mutant p53 increases secretion of MMP-2. Similar results were seen with cells from
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washed with colorless isotonic saline to remove serum, and were
further incubated for 24 h in neutral red-free Dulbecco’ medium
supplemented with 1.5% charcoal-treated estrogen-depleted
serum and 1% neutral red-free Matrigel, including estradiol at
the concentrations indicated in each experiment. Subsequently,
cells were processed as previously indicated [15]. Cells showed no
deﬁned ﬂuorescence after reaction with a negative control IgG in
contrast to the reactivity seen with the speciﬁc monoclonal
antibodies used.
2.8. Statistical studies
Standard deviations (S.D.) were used to determine a statistically
signiﬁcant difference in the median values shown for metabolic
activity/cell viability and similar assays. These were carried out in
quadruplicate and repeated at least 2 times. Generally, S.D. results
usually were within 5% with a 95% statistical signiﬁcance (n = 4).
The criterion for statistical signiﬁcance was taken as p < 0.05 by
Student’s t test, whenever indicated by *.
3. Results
3.1. Mutant p53 R175H induces EMT, losses in p21WAF1, PUMA,
cytokeratin 18 and secretion of MMP-2
Introducing the mutant p53 R175H into wt p53 MCF7 cells
generated a ERa+ cell line with both wt and mutated p53 proteins
co-expressed [5,15]. Inactivation of the wt p53 allele by a mutant
p53 possibly involves the interference of the latter with the wt
p53 homotetramer needed for its transcriptional DNA binding
activity [5]. Epithelial morphology was dramatically changed uponFig. 2. Mutant p53 R175H increases ERa expression and the % of ERa+ cells coexpressi
cytometry and immune blotting. (C–F) Laser scanning cytometry was used to analyze co
associated Ki67, in cells treated with scrambled or Bcl-2/Bcl-xL speciﬁc oligonucleotide s
demonstrated [37]. The results shown were similar in 2 different experiments.introduction of a mutant p53 R175H into wt p53 MCF-7 cells,
concomitantly with an extensive loss of both E-cadherin and
keratin 18, and the appearance of mesenchymal-looking cells
(Fig. 1A). Immune blotting conﬁrmed that cells expressing the
mutant p53 R175H decreased expression of wt p53 regulated
proteins PUMA and p21WAF1, seen in cells with p53 dysfunction
[33,44]. This was paralleled by induction of mesenchymal vimentin
[22] and proliferation-associated cyclin A [45], reciprocally with loss
of cytokeratin 18 and E-cadherin (Fig. 1B). These changes correlated
with greater secretion of the matrix-metalloprotease MMP-2 [34],
preferentially evident in mutant p53 R175H (Fig. 1C).
3.2. Percentage of proliferating Ki67+/ERa+ cells is susceptible to Bcl-
2/Bcl-xL and is increased by mutant p53
Since co-expression of ERa+ and the proliferation-associated
marker Ki-67 occurs with ERa+ breast cancer progression [2,3], and
ERa can activate cell proliferation and the expression of anti-
apoptotic genes like Bcl-2/Bcl-xL in ERa-positive breast cancer
cells [35,36], laser scanning cytometry and immune blotting were
used to show that ERa+ expression is increased by mutant p53
R175H in MCF-7 cells, (Fig. 2A and B). Cytometric analysis of the co-
expression of ERa+ positive cells relative to Ki67+ proliferating
cells, revealed an increase in the % of proliferating Ki67+/ERa+
mutant p53 cells (Fig. 2C and D). Moreover, exposure to a
scrambled oligonucleotide sequence revealed 17.8% of Ki67+ERa+
proliferating wt p53 cells compared to 34.4% Ki67+ERa+ prolifer-
ating mutant p53 R175H cells (quadrant 2, Fig. 2E and F). In
contrast, the % of Ki67+/ERa+ co-expressing cells was diminished
by the previously validated speciﬁc Bcl-2/Bcl-xL anti-sense
oligonucleotide [38] in more than 50%, irrespective of p53
mutational status (quadrant2, Fig. 2D and E). No comparableng Ki67. (A and B) Expression of ERa was analyzed respectively by laser scanning
-expression of cells labeled with antibodies directed against ERa and proliferation-
equences. Functional validation of these antisense oligonucleotides was previously
Fig. 3. Mutant p53 R175H decreases dependence on estradiol and MEK inhibition for cyclin A expression. Laser scanning cytometry shows that proliferation associated cyclin
A is preferentially increased in mut p53 MCF-7 cells cultured in estrogen-depleted medium supplemented with the indicated estradiol concentrations, including 10 mM of
MEK inhibitor UO126, whenever indicated. These results were consistently seen in 2 separate experiments.
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Ki67+ proliferating cells (quadrant 4, Fig. 2D and F)
3.3. mut p53 R175H decreases dependence on estradiol and MEK
activation for cyclin A expression
Inhibition of MEK/ERK activation using speciﬁc inhibitors is
known to block DNA synthesis in wt p53 MCF-7 cells [26–30]. We
now investigated by in situ laser scanning cytometry whether
introducing mutant p53 R175H into MCF-7 cells modiﬁed their
response to estrogen in the presence of UO126, a well known MEK
inhibitor [31], under estrogen depletion. This revealed 26.8% of
proliferation-associated cyclin A in wt p53 MCF-7 cells exposed to
10 nM E2, and essentially background proliferation in the absence
of exogenous E2 or when 10 nM E2 was supplemented with 10 mM
UO126 (Fig. 3A, C and E). No comparable dependence was seen in
mutant p53-expressing cells, which reproducibly expressed higher
proliferation-associated cyclin A than their matched wt p53
counterparts (Fig. 3B, D and F).
3.4. 3-Bromopyruvate toxicity is preferential for mut p53 cells
Since proliferation leads to high glucose consumption, we
compared the effect of the well known glycolytic inhibitor2-deoxyglucose [40] with that of 3-bromopyruvate [41–43], in
genetically-matched MCF-7 cells differing in their p53 status. Cells
seeded for 20 h in complete medium with 10% serum and 20 mM
glucose were transferred to glucose-free medium supplemented
with 5 mM glucose and 5% dialyzed serum for 48 h, to measure cell
viability [34]. This revealed selective toxicity of 75 mM 3-BrPA
towards mutant p53 cells, with no comparable selectivity of
2.5 mM 2-deoxyglucose, which was inhibitory irrespective of p53
status similarly (Fig. 4A). Survival studies also showed preferential
toxicity of 3-BrPA towards mutant p53 cells when assayed 5 days
later (Fig. 4B).
3.5. p53 siRNA increases estradiol signaling, resistance to MEK
inhibition, and susceptibility to 3-bromopyruvate in wt p53 MCF-7
cells
Although the consequences of p53 mutation are not identical to
those of gene silencing [15], we carried out some assays in wt p53
MCF-7 cells in which p53 siRNA was introduced at high efﬁciency
by electroporation to silence wt p53 expression compared to that
seen in the same cells in which scrambled negative-control siRNA
was similarly electroporated. Within 3 days of electroporation,
cells were assayed by plating them in medium supplemented with
estradiol-free serum and E2 concentrations indicated in each case,
Fig. 4. Mutant p53R175H increases susceptibility to 3-bromopyruvate in MCF-7 cells. Cells seeded overnight in complete medium with 20 mM glucose and 10% serum, were
washed to remove glucose and serum. Subsequently, cells were exposed for 72 h in glucose-free medium with 5 mM glucose and 5% dialyzed serum, for subsequent metabolic
activity assay. Relative cell viability in control cells and those treated with the indicated concentrations of 3-bromopyruvate (3-BrPA) or 2-deoxyglucose for 48 h was
measured by the Alamar Blue assay described under Section 2. Relative cell survival after exposure to 3-bromopyruvate was assessed after ﬁxing the cells in 70% ethanol and
staining with 0.5% crystal violet. These results obtained in quadruplicate were consistent in 3 separate experiments.
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blotting revealed that p53 siRNA decreased p53 protein expression
when normalized to reference actin levels (Fig. 5A). Relative cell
proliferation independently of MEK inhibition with UO126 or
exogenous estradiol was preferentially decreased by p53 silencing
(Fig. 5B and C). Reciprocally, loss of cell proliferation by 3-
bromopyruvate (BrPA) was increased by p53 siRNA (Fig. 5D). Taken
together, these observations are compatible with the results
shown in Figs. 3 and 4, implying that p53 inactivation by mutation
or silencing decreases dependence on exogenous estradiol and
MEK inhibition, but confers susceptibility to 3-BrPA in MCF-7 ERa+
breast carcinoma cells.
4. Discussion
EMT is important in breast cancer progression, but its diverse
consequences on autocrine proliferation and glycolysis are
incompletely understood. Using different isolates of genetically-
matched breast cancer MCF-7 cells with unequal p53 genotype
[15], we found that transducing mutant p53 R175H into ERa+
breast cancer MCF-7 cells, induces EMT and proliferation in
response to restrictive amounts of estrogen. This correlated with
higher estrogen receptor alpha (ERa) expression and increased co-
expression of the estrogen receptor ERa+ and the proliferation-
associated marker Ki-67 compared to their matched wt TP53
counterparts. We also showed that a previously validated Bcl-2/
Bcl-xL bispeciﬁc antisense oligonucleotide [37] decreased the
ERa+/Ki67+ proliferating population, irrespective of their p53status in agreement with studies demonstrating that ERa can
activate proliferation and expression of anti-apoptotic genes like
Bcl-2 in mutant p53 MCF-7 cells [35,36]. Moreover, both Bcl-2 and
Bcl-xL are known to be important in regulating cell proliferation
through their effects on glucose metabolism [46]. Our ﬁndings also
imply that p53 inactivation in MCF-7 cells reported to increase
EGF-R activation [15], also promotes adaptive hypersensitivity to
estradiol [46], supporting the link between EGFR/ERK activation
and ERa [36]. This interpretation is compatible with results
reporting that greater ERa expression and germline disruption of
one p53 allele increased extracellular signal-regulated kinase 1/2
(ERK1/2) and female breast cancer risk [11]. Since phosphorylation
at serines 104 and 106 by Erk1/2/MAPK is important for ERa
activity [29] and this pathway mediates response to anti-estrogens
[26–30], we also investigated whether the decreased dependence
on estrogen for cell proliferation induced by mutant p53R175H
also involved resistance to MEK inhibitors like UO126 [31]. It was
indeed seen that mutant p53 R175H induces MEK-independent
proliferation. Whereas expression of proliferation-associated
cyclin A [45] was dependent on estradiol and inhibited by the
MEK inhibitor UO126 in wt p53 cells [31], these restrictions did not
occur in cells with mutant p53 R175H, which showed higher
proliferation-associated cyclin A in the presence of the MEK
inhibitor and with low estradiol, compared to those with wt p53
(Fig. 3). Mutant p53 R175H cells which undergo EMT and
proliferate irrespective of low estrogen and chemical MEK
inhibition are likely to consume more glucose to support estrogen
modulated energy consumption [38,39]. Nevertheless, it was
Fig. 5. p53 siRNA electroporation increases estradiol signaling resistance to MEK inhibition, and 3-BrPA sensitivity in wt p53 MCF-7 cells. Cells electroporated with p53 siRNA
or negative control sequences were assayed for: (A) changes in p53 expression normalized to actin by immune blotting; (B) decreased dependence on MEK inhibition with
5 mM UO126 for proliferation measured by Alamar Blue ﬂuorescence; (C) enhanced response to estradiol (E2) measured by Alamar Blue ﬂuorescence and (D) relative survival
in response to 3-BrPA evidenced by Alamar Blue. These results shown are representative of 2 different experiments, in which (B) and (C) were carried out at n = 8.
M. Rieber, M. Strasberg-Rieber / Biochemical Pharmacology 88 (2014) 169–177 175noteworthy that milimolar levels of 2-deoxyglucose [40] exerted a
comparable inhibitory effect against MCF-7 cells irrespective of
their p53 status. This was in contrast to the higher and preferential
toxicity of micromolar concentrations of the pyruvate analogFig. 6. Decreased dependence on estradiol, and MEK inhibition and EMT induced by m
cancer cells. (Left) Breast carcinoma MCF-7 cells transduced with empty vector exhibit w
cytoskeletal keratin 18. (Right) Stable transduction of a R175H p53 mutation causes epit
keratin 18. Functional consequences of p53 dysfunction are proliferation with dimin
3-bromopyruvate.3-BrPA [43] towards mutant p53 MCF-7 cells (Fig. 4). Moreover,
p53 siRNA electroporation which causes transient p53 silencing
promoted increased proliferation in response to lower estradiol
and greater susceptibility to 3-BrPA, supporting the assertion thatutant p53 R175H confer greater susceptibility to 3-bromopyruvate in ERa+ breast
t p53 function and epithelial organization mediated by intercellular E-cadherin and
helial disorganization, and EMT in MCF-7 cells. This results in lower E-cadherin and
ished dependence on estrogen and MEK inhibition, and greater susceptibility to
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estrogen signaling and susceptibility to 3-BrPA. The greater
efﬁcacy of 3-BrPA against ERa+ MCF-7 cells with p53 inactivation
compared to that of 2-deoxyglucose may be due to the fact that this
pyruvate antagonist not only is capable of inhibiting both
glycolysis and mitochondrial oxidative phosphorylation [41–43],
but also can act as an anti-oxidant [47], in contrast to 2-
deoxyglucose which preferentially acts as a hexokinase inhibitor
of glycolysis [40].
Our Fig. 6 summary and our overall results suggests that
mutant p53 R175H or p53 dysfunction might antagonize response
to anti-estrogenic therapy, by lowering the threshold of estrogen
required for growth. This may occur because mutant p53 could
help to counteract proteasomal degradation of ERa+ and indirectly
increase expression of this receptor [48]. Another consequence of
the p53 R175H mutation on ERa+ breast cancer cells is the
diminished ability of the MEK inhibitor, UO126 [31,49] to
counteract cell proliferation. Our results suppressing wt p53
function by mutation or silencing in MCF-7 cells which is one of the
best pre-clinical models for TP53/ERa+ breast cancer cells, are
compatible with data from breast cancer patients showing
persistent activation of the MAPK pathway with diminished
response to tamoxifen but not chemotherapy [27,50,51]. Taken
together, our results support the rationale of testing ERa+ breast
cancers for p53 mutation to prevent resistance to selective
estrogen receptor modulator (SERM) treatments [27,50–52].
Translational research recently demonstrated that p53 dysfunc-
tion and active estrogen receptor (ER) signalling signiﬁcantly
inﬂuence survival and are prognostically most relevant in ERa+
breast cancers [27,50–53]. This report implies that 3-BrPA or
similar molecules capable of targeting both glycolysis and
mitochondrial respiration may be helpful as adjuvants in endo-
crine therapy against ERa+ breast cancers with inactivated p53.
This research was carried out in vitro with cultured breast
cancer cells and did not require approval from our bioethical
committee. Hence, this study is in accordance with the Code of
Ethics of the World Medical Association (Declaration of Helsinki)
for experiments involving humans.
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